About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
SMART QUOTES
Smart
Quotes
Cohance Lifesciences Ltd.
Industry :
Pharmaceuticals & Drugs
BSE Code
543064
ISIN Demat
INE03QK01018
Book Value
61.79
NSE Code
COHANCE
Dividend Yield %
0.00
Market Cap
344367.81
P/E
132.66
EPS
6.79
Face Value
1
BSE
NSE
04-Sep-2025
BSE
NSE
NSE F & O
04-Sep-2025
BSE
NSE
NSE F & O
Last Price
900.15
Net Change
-3.9
% Change
-0.43%
Prev.Close
904.05
Open
905.00
High
908.50
Low
893.35
Volume
148924
Last Price
899.30
Net Change
-5.7
% Change
-0.63%
Prev.Close
905.00
Open
913.95
High
913.95
Low
892.75
Volume
1313975
Value
134029474
Best Buy
0.00
Best Sell
0.00
Best Quantity
0
Sell Quantity
0
Today's Range
908.50
52-Week High
1359.00
52-Week Low
856.90
Value
1182558466.95
Best Buy
899.30
Best Sell
0.00
Best Quantity
101
Sell Quantity
0
Today's Range
913.95
52-Week High
1360.00
52-Week Low
856.30
Open Price
High Price
Low Price
Last Price
Prev Close
Change
% Change
Average Price
Underlying Value
Number of contracts traded
Turnover in Rs. Lakhs
Open Interest
Change in O I
% Change in O I
%
Today
|
1W
|
1M
|
1Y
You need to upgrade your Flash Player
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
0
Price
0.00
Best Bid
Best Offer
Quantity
101
Price
899.30
Quantity
0
Price
0.00
Best Bid
Best Offer
Quantity
Price
Quantity
Price
Holding Details
More
Latest Corporate Events
Bonus
1 : 1
25-Sep-20
Book Closure
07-Aug-24
09-Aug-24
Dividend
100 %
12-Sep-22
Company News
14-08-2025
USFDA completes GMP inspe...
12-08-2025
Cohance Lifesciences to i...
20-06-2025
Cohance Lifesciences ente...
26-05-2025
Cohance Lifesciences rece...
26-05-2025
Cohance Lifesciences gain...
25-04-2025
Suven Pharmaceuticals inf...
28-02-2025
Suven Pharmaceuticals inf...
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.
